Abstract Change/Withdrawal Deadline: August 25, 2025, at 12:00 PM (ET) Abstract Eligibility. As you prepare your submission to the Meeting, please make note of the following details: Summaries of new, ...

Meeting Abstract: 2025 ASCO Annual Meeting II. Free access. Head and Neck Cancer. June 04, 2025. Share on. NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to ...

Abstract Background. The benefit of regional nodal irradiation in the treatment of breast cancer is well established for patients with pathologically positive axillary nodes, ...

Abstract Background. Women receiving endocrine therapy for hormone receptor (HR)–positive breast cancer or its prevention among those at high risk for breast cancer commonly have vasomotor symptoms.